ATE290079T1 - Metabotropische gaba(b) rezeptoren, rezeptoren- spezifische liganden und deren anwendungen - Google Patents

Metabotropische gaba(b) rezeptoren, rezeptoren- spezifische liganden und deren anwendungen

Info

Publication number
ATE290079T1
ATE290079T1 AT97908260T AT97908260T ATE290079T1 AT E290079 T1 ATE290079 T1 AT E290079T1 AT 97908260 T AT97908260 T AT 97908260T AT 97908260 T AT97908260 T AT 97908260T AT E290079 T1 ATE290079 T1 AT E290079T1
Authority
AT
Austria
Prior art keywords
receptor
gabab
proteins
receptors
gabab receptor
Prior art date
Application number
AT97908260T
Other languages
English (en)
Inventor
Klemens Kaupmann
Bernhard Bettler
Helmut Bittiger
Wolfgang Froestl
Stuart John Mickel
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE290079T1 publication Critical patent/ATE290079T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97908260T 1996-05-30 1997-03-19 Metabotropische gaba(b) rezeptoren, rezeptoren- spezifische liganden und deren anwendungen ATE290079T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65571696A 1996-05-30 1996-05-30
US75609196A 1996-11-22 1996-11-22
PCT/EP1997/001370 WO1997046675A1 (en) 1996-05-30 1997-03-19 Metabotropic gaba[b] receptors, receptor-specific ligands and their uses

Publications (1)

Publication Number Publication Date
ATE290079T1 true ATE290079T1 (de) 2005-03-15

Family

ID=27097014

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97908260T ATE290079T1 (de) 1996-05-30 1997-03-19 Metabotropische gaba(b) rezeptoren, rezeptoren- spezifische liganden und deren anwendungen

Country Status (9)

Country Link
EP (1) EP0907731B1 (de)
JP (3) JP4131568B2 (de)
AT (1) ATE290079T1 (de)
AU (1) AU2028497A (de)
CA (1) CA2254862A1 (de)
DE (1) DE69732631T2 (de)
ES (1) ES2239352T3 (de)
PT (1) PT907731E (de)
WO (1) WO1997046675A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9772698A (en) 1997-10-27 1999-05-17 Astrazeneca Ab New nucleotide sequences
JP2002502859A (ja) * 1998-02-05 2002-01-29 メルク エンド カムパニー インコーポレーテッド 新規ｇａｂａｂ受容体ｄｎａ配列
EP0937777A3 (de) * 1998-02-20 1999-11-24 Smithkline Beecham Plc GABA Rezeporen und deren Anwendungen
AU768422B2 (en) * 1998-04-03 2003-12-11 Astrazeneca Ab G-protein fusion receptors and chimeric GABAb receptors
WO1999051636A2 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Gaba b receptor
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
WO1999058567A1 (en) * 1998-05-08 1999-11-18 Smithkline Beecham Corporation GABAB1b RECEPTOR
AUPP438498A0 (en) * 1998-06-29 1998-07-23 Garvan Institute Of Medical Research Novel Gaba-B receptor
WO2000012106A1 (en) * 1998-09-01 2000-03-09 Smithkline Beecham Corporation Gabab1aa receptor
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
ATE343634T1 (de) * 1998-09-07 2006-11-15 Glaxo Group Ltd Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere
GB9906882D0 (en) * 1999-03-25 1999-05-19 Novartis Ag Organic compounds
SE9901659D0 (sv) 1999-05-06 1999-05-06 Astra Ab New methods
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
US6787646B1 (en) * 1999-11-12 2004-09-07 Immusol, Inc. Tumor suppressor molecules and methods of use
DE19955408A1 (de) * 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
WO2004083855A1 (en) * 2003-03-19 2004-09-30 Solvo Biotechnology, Inc. Method for the identification of cells specifically modulating slow inhibition in the neocortex
CN102532197A (zh) * 2010-12-24 2012-07-04 中国科学院上海药物研究所 一类光亲和标记双功能探针分子及其制备方法和应用
CN108588087B (zh) * 2018-05-16 2022-06-03 南京农业大学 一种提高植物抗病性的基因GmLecRK-R及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids

Also Published As

Publication number Publication date
DE69732631T2 (de) 2005-12-29
PT907731E (pt) 2005-07-29
EP0907731A1 (de) 1999-04-14
DE69732631D1 (de) 2005-04-07
JP4131568B2 (ja) 2008-08-13
JP2007289188A (ja) 2007-11-08
ES2239352T3 (es) 2005-09-16
EP0907731B1 (de) 2005-03-02
AU2028497A (en) 1998-01-05
JP2008113662A (ja) 2008-05-22
JP2000515005A (ja) 2000-11-14
WO1997046675A1 (en) 1997-12-11
CA2254862A1 (en) 1997-12-11
JP4202403B2 (ja) 2008-12-24

Similar Documents

Publication Publication Date Title
DE69732631D1 (de) Metabotropische gaba(b) rezeptoren, rezeptoren-spezifische liganden und deren anwendungen
Meder et al. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23
Clark et al. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR).
Claeysen et al. Cloning, expression and pharmacology of the mouse 5-HT4L receptor
Lai et al. Identification of a δ isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes
ATE405589T1 (de) Für den snorf25-rezeptor kodierende dna
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
US5665859A (en) Molecules influencing the shedding of the TNF receptor, their preparation and their use
BG109433A (en) RET (RetL) Lead for Stimulating Nerve and Rat Growth
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
Hsu et al. Selective deamidation of recombinant human stem cell factor during in vitro aging: isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers
Viollet et al. Molecular pharmacology of somatostatin receptors
JPH04506752A (ja) チロトロピンレセプター活性を有するポリペプチド、このレセプターとポリペプチドとをコードする核酸、そしてこのようなペプチドの利用
PT973794E (pt) Receptores de netrina
Heller et al. Analysis of function and expression of the chick GPA receptor (GPAR α) suggests multiple roles in neuronal development
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
Steeg et al. Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity
WO1997000952A3 (en) A human edg-2 receptor homolog
JP3989536B2 (ja) ガラニンレセプター、核酸、形質転換細胞、およびそれらの使用
DE69832156D1 (de) Zusammensetzungen und verfahren des synaptischen aktivierungsproteins
MX9709849A (es) Receptor de quimiocina de la proteina g humana o hdgnr10.
Grenningloh et al. Molecular cloning of the antagonist-binding subunit of the glycine receptor
ATE382637T1 (de) Rezeptor-tyrosine-kinase gene
Grimmelikhuijzen et al. The peptidergic nervous system of coelenterates
Carnazzi et al. Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0907731

Country of ref document: EP